Co-Authors
This is a "connection" page, showing publications co-authored by GILBERT COTE and NANCY DUGAL PERRIER.
Connection Strength
1.195
-
Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016 11; 26(11):1553-1562.
Score: 0.142
-
Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center. Horm Cancer. 2016 08; 7(4):279-87.
Score: 0.138
-
Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature. Int J Surg. 2016 Jul; 31:10-6.
Score: 0.138
-
RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015 Mar; 100(3):788-93.
Score: 0.125
-
Preoperative multiple endocrine neoplasia type 1 diagnosis improves the surgical outcomes of pediatric patients with primary hyperparathyroidism. J Pediatr Surg. 2014 Apr; 49(4):546-50.
Score: 0.116
-
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol. 2011 Aug 23; 7(10):596-607.
Score: 0.099
-
Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006 May; 30(5):643-53.
Score: 0.069
-
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
Score: 0.044
-
Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery. 2019 01; 165(1):58-63.
Score: 0.041
-
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
Score: 0.039
-
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. Surgery. 2018 01; 163(1):212-217.
Score: 0.038
-
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 08 01; 102(8):2807-2813.
Score: 0.037
-
All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017 04; 16(2):283-289.
Score: 0.037
-
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
Score: 0.030
-
Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery. 2011 Dec; 150(6):1143-52.
Score: 0.025
-
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25.
Score: 0.024
-
Recent advances in thyroid cancer. In brief. Curr Probl Surg. 2008 Mar; 45(3):149-51.
Score: 0.019
-
Recent advances in thyroid cancer. Curr Probl Surg. 2008 Mar; 45(3):156-250.
Score: 0.019
-
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun; 15(6):531-44.
Score: 0.016